Chologene Diarrhö, Stiefkind der chronischen Diarrhö – Prävalenz, Diagnostik und Therapie

Die chologene Diarrhö ist eine der häufigsten nicht diagnostizierten Ursachen der chronischen Diarrhö, der zahlreiche verschiedene Pathophysiologien zugrunde liegen können. Auch nach Ausschlussdiagnostik der häufigeren Ursachen verbleiben bis zu 5% der Bevölkerung von einer ungeklärten chronischen Diarrhö betroffen. In diesem Kollektiv findet sich in bis zu 50% als Ursache eine chologene Diarrhö.

Abstract

The various pathophysiologies leading to bile acid diarrhea are well characterized. In this way, bile acid diarrhea can be divided into primary, secondary and tertiary subtypes. Common to all causes is the increased amount of bile acids in the colon and in the faeces and the resulting secretory-osmotic diarrhea, in more severe forms in combination with steatorrhea. The diagnosis of bile acid diarrhea follows a clear algorithm which, in addition to the search for the cause and possibly a therapeutic trial, recognizes the ⁷⁵SeHCAT test as the reference method for the detection of an increased loss of bile acids. In view of the chronic nature of the symptoms and the need for permanent, lifelong therapy, the use of a one-time, reliable diagnostic test is justified, though the test is currently only available at a few centers. In addition to the treatment of identifiable underlying diseases, the current treatment includes the use of drugs that bind bile acids, with additional nutritional recommendations and vitamin substitutions.

The present review article summarizes the pathophysiology and importance of bile acid diarrhea and discusses the current approach towards diagnosis and treatment.

Schlüsselwörter

chologene Diarrhö - Diarrhö - Gallensäurenverlust - SeHCAT-Test

Key words

bile acid diarrhea - diarrhea - bile acid loss - SeHCAT test

Publication History

Article published online:
14 December 2022

• Literatur

• 1 Shah SL, Janisch NH, Crowell M. et al. Patients With Irritable Bowel Syndrome Are Willing to Take Substantial Medication Risks for Symptom Relief. Clin Gastroenterol Hepatol 2020;
• 2 Wedlake L, A'Hern R, Russell D. et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-717
• 3 Sadowski DC, Camilleri M, Chey WD. et al. Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. J Can Assoc Gastroenterol 2020; 3: e10-e27
• 4 Arasaradnam RP, Brown S, Forbes A. et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut 2018; 67: 1380-1399
• 5 Chiang JY. Bile acid metabolism and signaling. Compr Physiol 2013; 3: 1191-1212
• 6 Di Ciaula A, Garruti G, Lunardi Baccetto R. et al. Bile Acid Physiology. Ann Hepatol 2017; 16: s4-s14
• 7 Vijayvargiya P, Camilleri M. Update on Bile Acid Malabsorption: Finally Ready for Prime Time?. Curr Gastroenterol Rep 2018; 20: 10
• 8 Fromm H, Malavolti M. Bile acid-induced diarrhoea. Clin Gastroenterol 1986; 15: 567-582
• 9 Morris KA, Haboubi NY. Pelvic radiation therapy: Between delight and disaster. World J Gastrointest Surg 2015; 7: 279-288
• 10 Thaysen EH, Pedersen L. Idiopathic bile acid catharsis. Gut 1976; 17: 965-970
• 11 van Tilburg AJ, de Rooij FW, van den Berg JW. et al. Primary bile acid diarrhoea without an ileal carrier defect: quantification of active bile acid transport across the ileal brush border membrane. Gut 1991; 32: 500-503
• 12 Hofmann AF, Mangelsdorf DJ, Kliewer SA. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol 2009; 7: 1151-1154
• 13 Slattery SA, Niaz O, Aziz Q. et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015; 42: 3-11
• 14 Lin S, Sanders DS, Gleeson JT. et al. Long-term outcomes in patients diagnosed with bile-acid diarrhoea. Eur J Gastroenterol Hepatol 2016; 28: 240-245
• 15 Wenzel H. [Primary bile acid diarrhea in a community gastroenterology practice]. Z Gastroenterol 2019; 57: 734-739
• 16 Bala L, Ghoshal UC, Ghoshal U. et al. Malabsorption syndrome with and without small intestinal bacterial overgrowth: a study on upper-gut aspirate using 1H NMR spectroscopy. Magn Reson Med 2006; 56: 738-744
• 17 Sauter GH, Moussavian AC, Meyer G. et al. Bowel habits and bile acid malabsorption in the months after cholecystectomy. Am J Gastroenterol 2002; 97: 1732-1735
• 18 Gracie DJ, Kane JS, Mumtaz S. et al. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil 2012; 24: 983-e538
• 19 Fisher M, Spilias DC, Tong LK. Diarrhoea after laparoscopic cholecystectomy: incidence and main determinants. ANZ J Surg 2008; 78: 482-486
• 20 Sciarretta G, Furno A, Mazzoni M. et al. Post-cholecystectomy diarrhea: evidence of bile acid malabsorption assessed by SeHCAT test. Am J Gastroenterol 1992; 87: 1852-1854
• 21 Ruiz-Campos L, Gisbert JP, Ysamat M. et al. Systematic review with metaanalysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy. Aliment Pharmacol Ther 2019; 49: 242-250
• 22 Lindstrom CG. “Collagenous colitis” with watery diarrhoea – a new entity?. Pathol Eur 1976; 11: 87-89
• 23 Lazenby AJ, Yardley JH, Giardiello FM. et al. Lymphocytic (“microscopic”) colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol 1989; 20: 18-28
• 24 Ung KA, Kilander AF, Lindgren A. et al. Impact of bile acid malabsorption on steatorrhoea and symptoms in patients with chronic diarrhoea. Eur J Gastroenterol Hepatol 2000; 12: 541-547
• 25 Bannaga A, Kelman L, O'Connor M. et al. How bad is bile acid diarrhoea: an online survey of patient-reported symptoms and outcomes. BMJ Open Gastroenterol 2017; 4: e000116
• 26 Layer P, Andresen V, Pehl C. et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol 2011; 49: 237-293
• 27 Fernandez-Banares F, Esteve M, Salas A. et al. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol 2007; 102: 2520-2528
• 28 Lyutakov I, Ursini F, Penchev P. et al. Methods for diagnosing bile acid malabsorption: a systematic review. BMC Gastroenterol 2019; 19: 185
• 29 Schalch D, Scharmann A. Selected aspects of individual dosage monitoring. Strahlenschutz Forsch Prax 1988; 30: 11-18
• 30 Fani B, Bertani L, Paglianiti I. et al. Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique. Gastroenterol Res Pract 2018; 2018: 2097359
• 31 Keller J, Franke A, Storr M. et al. Clinically relevant breath tests in gastroenterological diagnostics – recommendations of the German Society for Neurogastroenterology and Motility as well as the German Society for Digestive and Metabolic Diseases. Z Gastroenterol 2005; 43: 1071-1090
• 32 Mönnikes H. Gallensäurenmalabsorption – Eine Übersicht zu Differentialdiagnostik und Therapieoptionen. Forum Sanitas 2020; 2: 3-5
• 33 Turner JM, Pattni SS, Appleby RN. et al. A positive SeHCAT test results in fewer subsequent investigations in patients with chronic diarrhoea. Frontline Gastroenterol 2017; 8: 279-283
• 34 Westergaard H. Bile Acid malabsorption. Curr Treat Options Gastroenterol 2007; 10: 28-33
• 35 Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: a review. Clin Ther 2015; 37: 2153-2179
• 36 Ratiopharm. Fachinformation Colestyramin-Ratiopharm, letzter Aufruf 20.12.2020. 1996
• 37 Arznei-Telegramm. Neuer Anionenaustauscher: Colesevelam (Cholestagel). 2008; 39: 57-58
• 38 Ärzteschaft Add. Neue Arzneimittel. Cholestagel (Colesevelam). Stand: 12.10.2010, letzter Aufruf 20.12.2020; Information der Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ); 2010
• 39 Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm 2002; 59: 932-939
• 40 Mutschler E. Arzneimittelwirkungen. 10. Aufl. Wissenschaftliche Verlagsgesellschaft; 2013
• 41 Ladas SD, Isaacs PE, Murphy GM. et al. Comparison of the effects of medium and long chain triglyceride containing liquid meals on gall bladder and small intestinal function in normal man. Gut 1984; 25: 405-411
• 42 Kapral C, Wewalka F, Praxmarer V. et al. Conjugated bile acid replacement therapy in short bowel syndrome patients with a residual colon. Z Gastroenterol 2004; 42: 583-589
• 43 Popovic OS, Jojic N, Necic D. Cholylsarcosine for bile acid deficiency caused by ileal resection. Dig Dis Sci 1999; 44: 1931-1932
• 44 Heydorn S, Jeppesen PB, Mortensen PB. Bile acid replacement therapy with cholylsarcosine for short-bowel syndrome. Scand J Gastroenterol 1999; 34: 818-823
• 45 Smith LH, Fromm H, Hofmann AF. Acquired hyperoxaluria, nephrolithiasis, and intestinal disease. Description of a syndrome. N Engl J Med 1972; 286: 1371-1375
• 46 Asplin JR. The management of patients with enteric hyperoxaluria. Urolithiasis 2016; 44: 33-43
• 47 Emmett M, Guirl MJ, Santa Ana CA. et al. Conjugated bile acid replacement therapy reduces urinary oxalate excretion in short bowel syndrome. Am J Kidney Dis 2003; 41: 230-237
• 48 listed na. The blind-loop syndrome. Lancet 1967; 1: 85-86
• 49 Hofmann AF, Poley JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 1972; 62: 918-934
• 50 Kwon RS, Carey MC. Do steroids ameliorate bile acid malabsorption in Crohn's disease?. Gut 2004; 53: 10-11
• 51 Borghede MK, Schlutter JM, Agnholt JS. et al. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea. Eur J Intern Med 2011; 22: e137-e140
• 52 Quigley EMM. The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO). Curr Gastroenterol Rep 2019; 21: 3
• 53 Andresen V, Montori VM, Keller J. et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6: 545-555
• 54 Camilleri M. What's in the pipeline for lower functional gastrointestinal disorders in the next 5 years?. Am J Physiol Gastrointest Liver Physiol 2019; 317: G640-G650
• 55 Walters JR, Johnston IM, Nolan JD. et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015; 41: 54-64
• 56 Camilleri M, Nord SL, Burton D. et al. Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea. Aliment Pharmacol Ther 2020; 52: 808-820
• 57 Vijayvargiya P, Camilleri M, Carlson P. et al. Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial. Clin Gastroenterol Hepatol 2020;
• 58 Wilcox C, Turner J, Green J. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Aliment Pharmacol Ther 2014; 39: 923-939
• 59 Riemsma R, Al M, Corro Ramos I. et al. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013; 17: 1-236
• 60 Fernandes DCR, Poon D, White LL. et al. What is the cost of delayed diagnosis of bile acid malabsorption and bile acid diarrhoea?. Frontline Gastroenterol 2019; 10: 72-76
• 61 Walters JRF, Arasaradnam R, Andreyev HJN. et al. Diagnosis and management of bile acid diarrhoea: a survey of UK expert opinion and practice. Frontline Gastroenterol 2020; 11: 358-363